{"a":[{"_":"Replimune’s twice-rejected melanoma drug prevails in FDA adcomm","$":{"href":"/biotech/replimunes-twice-rejected-melanoma-drug-prevails-fda-adcomm","hreflang":"en"}}]}
AdCompositivePositive
AI Analysis
Summary
Replimune's melanoma drug received a positive vote from an FDA advisory committee (10-3) after previously facing two FDA rejections. The favorable recommendation represents a significant development for the candidate's potential regulatory pathway.
Outcome Details
Advisory committee voted 10 to 3 in favor of the candidate's effectiveness
Importance:8/10
Sentiment:
0.80
melanomaFDAadvisory committeerejection history
Related Companies
Read the original article
Published by FierceBiotech on July 30, 2026 6:13 PM